Date: 2011-01-13
Type of information: Commercialisation agreement
Compound: Veregen® ointment (made from the extract of green tea leaves - catechins)
Company: MediGene AG (Germany) Laboratoires Expanscience (France )
Therapeutic area: Gynecology - Infectious diseases
Type agreement: commercialisation
marketing
Action mechanism:
Disease: external genital warts
Details: MediGene AG (Germany) has signed an exclusive license and supply agreement with Laboratoires Expanscience for the commercialization and marketing of Veregen® ointment in France. Laboratoires Expanscience will promote and distribute the drug for the treatment of genital warts.
Financial terms: MediGene is entitled to successive payments totaling approx. € 2.3 million, depending on the achievement of set milestones. The first milestone payment will become due upon initiation of the approval procedure in France. Furthermore, MediGene will supply Expanscience with drug product and obtain royalties on the sales revenue generated with Veregen® in the form of a double-digit percentage share.
Latest news: * On July 2, 2012, Medigene has announced that Veregen® for the treatment of genital warts has obtained marketing authorization in France. Market launch of Veregen® by Medigene's partner, Laboratoires Expanscience, is expected in 2013, upon conclusion of the reimbursable price-fixing procedure.
